Forward PE Ratio: 20.54
The forward PE ratio is 20.54 as of Thursday, July 9, 2026.
Forward PE Ratio (20.54) = Close Price ($216.00) / Consensus Forward EPS ($10.20)
STE Forward PE Ratio Metrics
FORWARD PE RATIO
20.54
STE Competitors' Forward PE Ratio
STERIS plc
Market Cap
$21.05B
Forward PE Ratio
20.54
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| STERIS plc (STE) | $21.05B | 20.54 |
| Labcorp Holdings Inc. (LH)vs › | $22.77B | 15.42 |
| Quest Diagnostics Incorporated (DGX)vs › | $23.03B | 19.37 |
| Viatris Inc. (VTRS)vs › | $19.03B | 6.75 |
| United Therapeutics Corporation (UTHR)vs › | $23.45B | 19.75 |
| BioNTech SE (BNTX)vs › | $23.51B | N/A |
| Incyte Corporation (INCY)vs › | $23.68B | 15.33 |
| Waters Corporation (WAT)vs › | $24.58B | 25.34 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.26B | 10.32 |
| Hologic, Inc. (HOLX)vs › | $16.97B | 17.21 |
Trailing vs Forward
Trailing P/E
26.4
reported TTM EPS
Forward P/E
20.5
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $10.20 implies +28.6% EPS growth vs the reported trailing $7.93.
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $216.00 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-03-31 | $11.16 | $10.90 – $11.25 | 6 | 19.4x |
| 2028-03-31 | $12.19 | $11.75 – $12.42 | 5 | 17.7x |
| 2029-03-31 | $13.20 | $13.06 – $13.34 | 2 | 16.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Forward PE Ratio FAQ
- What is the forward PE ratio for STERIS plc (STE)?
- The forward PE ratio for STE stock is 20.54.
Related Metrics
About STERIS plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Daniel A. Carestio